secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-122792
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapport Therapeutics Q3 net loss $17.5M; DPNP IND on clinical hold; cash $320.7M
--------------------------------------------------------------------------------

- Net loss $17.5M vs $8.7M prior year; R&D expense $15.5M (up from $7.6M) driven by clinical development.
- Cash, equivalents, and short-term investments $320.7M; expected to fund operations through end of 2026.
- RAP-219 Phase 2a focal epilepsy trial on track; topline data expected mid-2025. MAD-2 and PET results Q1 2025.
- FDA placed IND for diabetic peripheral neuropathic pain (DPNP) on clinical hold; focal epilepsy trial unaffected.
- Appointed four new board members (Rob Perez, Raymond Sanchez, Paul Silva, Wendy Young); Jeff Tong resigned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000095017024122792/0000950170-24-122792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000095017024122792/rapp-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer